Notably, BIRC5 has been explored as one of the hub ATGs in the prognostic signatures of breast cancer, prostate cancer, and human endometrial cancer, as well as GRID2 in gastric cancer and endometrial carcinoma (Yunyan et al., 2015; Hu et al., 2020; Qiu et al., 2020; Zhang et al., 2020; Chen et al., 2021). Here, GRID2 is linked to endometrial cancer.